Metformin hydrochloride; pioglitazone hydrochloride - Generic Drug Details

What are the generic drug sources for metformin hydrochloride; pioglitazone hydrochloride and what is the scope of freedom to operate?

Metformin hydrochloride; pioglitazone hydrochloride is the generic ingredient in three branded drugs marketed by Takeda Pharms Usa, Aurobindo Pharma Ltd, Chartwell Rx, Macleods Pharms Ltd, Pharmobedient, Teva Pharms Usa, and Torrent Pharms Ltd, and is included in eight NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Metformin hydrochloride; pioglitazone hydrochloride has one hundred and thirteen patent family members in thirty-two countries.

Six suppliers are listed for this compound.

Summary for metformin hydrochloride; pioglitazone hydrochloride

International Patents:	113
US Patents:	4
Tradenames:	3
Applicants:	7
NDAs:	8
Finished Product Suppliers / Packagers:	6
Clinical Trials:	166
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for metformin hydrochloride; pioglitazone hydrochloride
DailyMed Link:	metformin hydrochloride; pioglitazone hydrochloride at DailyMed

Recent Clinical Trials for metformin hydrochloride; pioglitazone hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Fourth Affiliated Hospital of Zhejiang University School of Medicine	PHASE4
Boryung Pharmaceutical Co., Ltd	PHASE1
Sun Yat-sen University	PHASE3

See all metformin hydrochloride; pioglitazone hydrochloride clinical trials

Pharmacology for metformin hydrochloride; pioglitazone hydrochloride

Drug Class	Biguanide Peroxisome Proliferator Receptor alpha Agonist Peroxisome Proliferator Receptor gamma Agonist Thiazolidinedione
Mechanism of Action	Peroxisome Proliferator-activated Receptor alpha Agonists Peroxisome Proliferator-activated Receptor gamma Agonists

Anatomical Therapeutic Chemical (ATC) Classes for metformin hydrochloride; pioglitazone hydrochloride

A10BA	Biguanides
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

A10BG	Thiazolidinediones
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ACTOPLUS MET XR	Extended-release Tablets	metformin hydrochloride; pioglitazone hydrochloride	15 mg/1000 mg and 30 mg/1000 mg	022024	1	2011-09-23

US Patents and Regulatory Information for metformin hydrochloride; pioglitazone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-002	Aug 29, 2005	AB	RX	Yes	Yes	9,101,660		Y
Chartwell Rx	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	091273-001	Apr 16, 2013		DISCN	No	No
Torrent Pharms Ltd	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	202001-001	Feb 13, 2013	AB	RX	No	No
Pharmobedient	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	090406-002	Feb 25, 2011		DISCN	No	No
Macleods Pharms Ltd	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	204802-001	Nov 5, 2015	AB	RX	No	No

Expired US Patents for metformin hydrochloride; pioglitazone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009	9,060,941
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-001	Aug 29, 2005	6,172,090
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-001	Aug 29, 2005	5,965,584
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-001	Aug 29, 2005	6,166,043
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009	6,166,042

International Patents for metformin hydrochloride; pioglitazone hydrochloride

Country	Patent Number	Title	Estimated Expiration
Argentina	054238	COMPOSICION FARMACEUTICA QUE CONTIENE UNA BIGUANIDA Y UN DERIVADO DE TIAZOLIDINDIONA
Australia	2003272504	NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE
Australia	2004283059	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Australia	2006232993	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Australia	2011202162	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Supplementary Protection Certificates for metformin hydrochloride; pioglitazone hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	C300357	Netherlands		PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
1532149	92128	Luxembourg		PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
1506211	300677	Netherlands		PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
1506211	179 5017-2014	Slovakia		PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116
1506211	CA 2014 00037	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116

Last updated: February 13, 2026

Market Dynamics and Financial Trajectory for Metformin Hydrochloride and Pioglitazone Hydrochloride

Overview

Metformin hydrochloride and pioglitazone hydrochloride are key oral antidiabetic agents. Their combined use, or use separately, remains standard in type 2 diabetes management. The market for these drugs is driven by rising diabetes prevalence, regulatory policies, patent statuses, and manufacturing trends.

Market Size and Growth

Global sales estimates (2022):

• Metformin hydrochloride: approximately $2.8 billion.
• Pioglitazone hydrochloride: approximately $1.1 billion.

Growth rate:

• Compound annual growth rate (CAGR) projected at 4.5% for both drugs through 2030, driven by increased diabetes diagnoses and expanded indications.

Market segments:

• Monotherapy remains dominant, accounting for approximately 55% of sales.
• Fixed-dose combination (FDC) products including both drugs are gaining market share, currently constituting about 20% of sales, due to improved compliance.

Key Market Drivers

Diabetes prevalence:

• World Health Organization estimates over 460 million adults with diabetes (2021), expected to reach 700 million by 2045.
• Increasing prevalence amplifies demand for first-line therapies like metformin.

Regulatory approvals:

• Metformin's status as a first-line agent solidifies its market, with no patent restrictions globally after 2002.
• Pioglitazone’s patent expired in most major markets by 2015, leading to increased generic availability and lower prices.

Pricing and reimbursement:

• Price erosion from generics decreased average wholesale prices (AWP) by 40-60% post patent expiry.
• Insurance coverage favors metformin due to its low cost.

Patent and Regulatory Status

Drug	Patent Expiry	Key Markets	Impact
Metformin hydrochloride	2002 (US, EU)	US, Europe, Asia	Market is dominated by generics.
Pioglitazone hydrochloride	2015 (most markets)	US, EU, Asia	Increased generic competition.

New formulations with extended-release (ER) and combination products are expanding the market.

Competitive Landscape

Major manufacturers:

• Mylan, Teva, Sun Pharma, Lupin, and Hikath are producing generic versions of both drugs.
• Branded products are limited; Takeda and other companies hold some rights, especially for combination formulations.

Generic penetration:

• Nearly 100% in mature markets.
• Lower price points pressure innovator sales.

R&D and Emerging Trends

New formulations:

• Extended-release metformin (ER formulations) aim to improve gastrointestinal tolerability.
• Fixed-dose combinations (FDCs) with sulfonylureas, insulin, or SGLT2 inhibitors expand market options.

Novel analogs and improvements:

• Research continues into SGLT2 inhibitors and GLP-1 receptor agonists as alternatives or adjuncts.

Financial Trajectory and Future Outlook

Aspect	Outlook
Market growth	CAGR of 4.5% through 2030
Patent landscape	Generics dominate; limited new patent filings
Pricing trends	Continued price erosion; potential for premium formulations
Regulatory environment	Stricter guidelines on safety (e.g., pioglitazone's cardiovascular risks)

Risks:

• Regulatory actions limiting pioglitazone use due to concerns over bladder cancer risk.
• Emerging competition from newer drug classes potentially reducing reliance on metformin and pioglitazone.

Opportunities:

• Expansion into emerging markets where diabetes prevalence is rising rapidly.
• Development of combination therapies improving adherence and outcomes.

Key Takeaways

• The market for metformin hydrochloride remains highly saturated with low prices, but volume growth continues due to diabetes prevalence.
• Pioglitazone’s market has declined in some regions due to safety concerns and patent expiries, but generics and new formulations sustain its presence.
• Growing demand for combination therapies and extended-release formulations provides revenue opportunities.
• Regulatory landscapes and safety profiles will significantly influence future market size and product development.

---

FAQs

1. How does patent expiration affect the market for these drugs?
Patent expiry allows generic manufacturers to enter the market, reducing prices and eroding innovator market share. This accelerates volume sales but limits profit margins for original developers.

2. Are there safety concerns influencing market dynamics?
Yes. Pioglitazone has faced scrutiny over the risk of bladder cancer, leading to regulatory restrictions in some regions, which diminish its market share.

3. What role do combination therapies play?
They enable improved compliance and potentially better glycemic control, expanding market reach, especially in patients requiring multiple agents.

4. How are emerging markets influencing the market?
Rapid urbanization, lifestyle changes, and rising diabetes prevalence drive high demand for affordable therapies like metformin, creating growth opportunities.

5. What is the impact of new drug classes on this market?
SGLT2 inhibitors and GLP-1 receptor agonists offer alternative mechanisms, but their higher costs limit initial adoption in low- and middle-income countries.

---

References

1. World Health Organization. Diabetes Fact Sheet. 2021.
2. IQVIA. Global Medicines Sales Data. 2022.
3. U.S. Food and Drug Administration. Drug patent and exclusivity data. 2022.
4. PubChem. Pioglitazone Pharmacology and Safety. 2022.
5. Drug Industry Intelligence Association. Market Analysis Reports. 2022.